Columns The MS Wire - A Column by Ed Tobias MS News That Caught My Eye Last Week: Nasal Spray Treatment, Anxiety Management, POMS, PoNS MS News That Caught My Eye Last Week: Nasal Spray Treatment, Anxiety Management, POMS, PoNS by Ed Tobias | April 5, 2021 Share this article: Share article via email Copy article link SPMS Patient First to Be Treated With Antibody Given via Nasal Spray How great is this? As someone who gave himself an injection in his thigh for many years and received IV infusions for many more, an MS antibody treatment sprayed into the nose is wonderful news. This approval only applies to one patient, however. A Phase 1 clinical trial is underway, and a Phase 2 is expected to begin later this year. I hope this nasal spray, which initially was intended to be an oral medication, proves to be safe and effective. For a first time, an immune-modulating antibody will be given via nasal administration to treat a person with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug Administration (FDA) approved a request to use the antibody — a fully human anti-CD3 monoclonal antibody called foralumab — under an Individual Patient Expanded Access Program, the therapy’s developer, Tiziana Life Sciences, announced in a press release. Click here to read the full story. *** Wise Will Seek FDA Approval for Digital Anxiety Management Therapy The technical description of this proposed anxiety treatment is a “gamified digital experience” designed for “attention bias modification.” In “people talk,” I think that translates to a digital game designed to divert a person’s attention away from stress triggers. But note that this therapy is being studied to treat people with two other conditions in addition to MS. Unfortunately, its manufacturer only intends to choose one of the three groups for its final product. Wise Therapeutics intends to seek U.S. Food and Drug Administration (FDA) approval of an anxiety management therapy for multiple sclerosis (MS), following the positive results of a clinical trial. In addition to conducting a proof-of-concept study in MS, Wise tested its digital technique — called attention bias modification (ABM) treatment — in alcohol use disorder and for perinatal anxiety among pregnant women. Click here to read the full story. *** PoNS Device to Help Adults in Rehab for Walking Problems Gets FDA Approval Last year, when the PoNS device was being developed, I wrote a column about it. I wondered if someone would be willing to have a mild electrical current applied to the tongue to improve their walking. I’m not sure I would, would you? The U.S. Food and Drug Administration (FDA) has authorized the use of a medical device called Portable Neuromodulation Stimulator or PoNS as a short-term treatment for walking difficulties in people with multiple sclerosis (MS). PoNS, developed by Helius Medical Technologies, is a noninvasive medical device that, when placed on the tongue, delivers mild electrical signals to the brain via two major cranial nerves. The mouthpiece is connected, via a cord, to a controller that is worn around the neck. By sending these electrical impulses, the device is believed to promote neuroplasticity — the brain’s ability to “rewire itself” in response to new experiences. Click here to read the full story. *** In Real World, Tysabri Lessens Disease Activity, Reduces Relapses in Pediatric-onset MS Pediatric-onset MS (POMS) is a diagnosis applied to patients under 16. It accounts for about 5% of all MS diagnoses. Tysabri isn’t yet approved to treat POMS, but as it and other disease-modifying therapies prove to be safe and effective for these young MS patients, I hope regulators move quickly to do so. Many neurologists believe that the earlier MS can be treated, the more likely it is that its progression can be slowed or stopped. Off-label treatment with Tysabri (natalizumab) significantly lessens disease activity and reduces the number of relapses per year in patients with pediatric-onset multiple sclerosis (POMS), real-world data from Portugal show. The treatment also was considered safe in this population, in agreement with earlier studies. These findings support the usefulness of Tysabri for treating MS patients who develop the disease during childhood, the researchers said. Click here to read the full story. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. He’s also the author of “The Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.” Ed and his wife split their time between the Washington, D.C. suburbs and Florida’s Gulf Coast, trying to follow the sun. Tags PoNS Comments Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program
